吡格列酮对肥胖女性体内脂肪生成的组织特异性影响
结果显示,吡格列酮组内脏脂肪占比显著下降、Matsuda指数升高,股部皮下脂肪组织新脂肪细胞形成显著增加,而腹部皮下脂肪组织无显著变化。
要点
- 吡格列酮16周可降低肥胖女性内脏脂肪占比并改善胰岛素敏感性。
- 体内脂肪生成增加具有脂肪库特异性,仅股部皮下脂肪显著。
- 未报告严重不良事件。
核心结论
- 吡格列酮可能使肥胖女性不同皮下脂肪库的体内脂肪生成呈现差异, protective的股部皮下脂肪生成速率增加。
研究设计与样本
- 主要终点为通过8周氘(2H)标记脂肪细胞DNA评估的体内细胞动力学。
主要发现
- 吡格列酮组相对安慰剂组内脏脂肪(VAT:总腹部AT,以%计)显著下降,p = 0.002。
- 吡格列酮组相对安慰剂组Matsuda指数升高(胰岛素敏感性改善),p = 0.04。
- 股部皮下脂肪组织新脂肪细胞形成显著增加(Δ = 3.3 ± 1.6%;p = 0.04),腹部皮下脂肪组织无显著变化(Δ = 2.0 ± 2.1%;p = 0.32)。
- 未报告严重不良事件。
关键数值与推荐
- 吡格列酮30 mg/日,干预16周。
- 内脏脂肪下降p = 0.002;Matsuda指数改善p = 0.04。
- 股部皮下脂肪新脂肪细胞形成Δ = 3.3 ± 1.6%,p = 0.04;腹部皮下Δ = 2.0 ± 2.1%,p = 0.32。
临床怎么用
- 提示吡格列酮改善代谢健康可能与内脏脂肪减少及股部皮下脂肪生成增加有关,支持脂肪库特异性效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: In vitro and rodent studies suggest that pioglitazone, a thiazolidinedione, can promote adipogenesis in adipose tissue (AT); however, there is a lack of in vivo studies in humans to support these findings. The objectives of this randomised, placebo-controlled, parallel-arm trial were to test if pioglitazone stimulates in vivo adipogenesis in the subcutaneous adipose tissue depots and if these measures were related to metabolic health outcomes in women with obesity. METHODS: Forty-one healthy women with obesity (20 black; 21 white; 29 ± 6 years; BMI 32.0 ± 1.7 kg/m2; 44.0 ± 3.6% body fat) were randomised to consume 30 mg/day of pioglitazone (n = 21) or placebo (n = 20) for 16 weeks. SAS v9.4 was used to generate the block randomisation code sequence (stored in password-protected files) with a 1:1 allocation ratio. The participants and study staff involved in assessing and analysing data outcomes were blinded to the group assignments. The trial was conducted at Pennington Biomedical Research Center and ended in 2016. At baseline and post-intervention, subcutaneous abdominal (scABD) and femoral (scFEM) AT biopsies were collected, and in vivo cellular kinetics (primary endpoint of the trial) were assessed by an 8 week labelling protocol of deuterium (2H) into the DNA of adipose cells. Body composition was measured by dual-energy x-ray absorptiometry (DXA), scABD and visceral AT (VAT) by MRI, ectopic fat by 1H-MRS, and insulin sensitivity by an OGTT. RESULTS: After the 16 week intervention, there was a significant decrease in visceral fat (VAT:total abdominal AT [as a %]; p = 0.002) and an increase in the Matsuda index (i.e. improved insulin sensitivity; p = 0.04) in the pioglitazone group relative to the placebo group. A significant increase in the formation of new adipocytes was observed in the scFEM (Δ = 3.3 ± 1.6%; p = 0.04) but not the scABD depot (Δ = 2.0 ± 2.1%; p = 0.32) in the pioglitazone group relative to the placebo group. No serious adverse events were reported. CONCLUSIONS/INTERPRETATION: Pioglitazone may elicit distinct differences in in vivo adipogenesis in subcutaneous adipose depots in women with obesity, with increased rates in the protective scFEM. Trial registration ClinicalTrials.gov NCT01748994 Funding This study was funded by R01DK090607, P30DK072476, and R03DK112006 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health. The Robert C. and Veronica Atkins Foundation. Graphical abstract.
引用
- White U, Fitch MD, Beyl RA, et al. Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: a randomised controlled trial. Diabetologia. 2020. PMID: 33001232. doi:10.1007/s00125-020-05281-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。